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Glycosphingolipids are integral constituents of cellular 
membrane, arranged in rafts, and with neoplasic cell anti-
social behavior, like uncontrolled cell growth, invasiveness, 
and metastatic potential. Aim: However, there are few studies 
about glycosphingolipids (GSL) expression in squamous 
cell carcinoma (SCC). Since GSL are known to be tumor-
associated markers we decided to perform a prospective 
study on the GSL profiles of SCC. Method: Specimens of 
33 SCC and normal mucosa were obtained and GSLs were 
extracted and purified by reverse-phase chromatography 
on C18 column and alkaline hydrolysis in methanol. GSLs 
were quantified using densitometry of orcinol-stained HPTLC 
plates. Result: A significant increase of GSLs in SCC (3.57µg/
mg) was observed as compared to normal mucosa (1.92µg/
mg). In SCC, an increase of 2 to 3 times in the amounts of 
CDH, CTH, Globoside, and GM3 was observed in comparison 
to normal mucosa. The identification of GM3 as well as its 
increased expression in SCC was confirmed unequivocally 
by HPTLC immunostaining and indirect immunofluorescence 
using MAb DH2 (anti-GM3). BY analyzing SCC and normal 
mucosa CMHs by GC/MS, normal mucosa expresses 
only glucosylceramide whereas SCC cells express both 
glucosylceramide and galactosylceramide. Conclusion: The 
increase in the amount of GSLs in tumor tissue may represent 
changes of cell membrane microdomains resulting from the 
malignant transformation process, which is responsible for 
greater cell-cell or cell-matrix interaction thereby increasing 
their potential for infiltration and metastasis.
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INTRODUCTION
Besides outlining cell limits, the cell membrane has 
other important functions. It is responsible for maintaining 
ion gradients, the communication with other cells and with 
the external medium through transmembrane receptors, 
located in specialized areas called microdomains2. Altera-
tions in microdomains and their components, GSLs among 
them, are related to malignant transformation processes, 
a much studied theme, especially in melanomas, breast, 
colon and lung cancers1.
The cell membrane is made up of a double lipid, 
and a protein layer, perpendicularly arranged, totally or 
partially soaked within both lipid layers2-4. Most cell mem-
brane lipids are phospholipids. Besides phospholipids, 
cholesterol and glycolipid molecules are also present in 
large amounts2,5 in the cell membrane. Glycosphingolipids 
(GSL) are the most abundant glycolipids in the cell mem-
brane, being formed by a ceramide molecule (sphingosine 
linked to a fatty acid) with one or more sugar residues 
linked to its primary carbon5, usually present in special-
ized areas known as microdomains2. These microdomains, 
or lipid rafts, are cell membrane areas, formed by GSL, 
cholesterol and proteins, which work as a platform where 
some proteins attach to, allowing them to act together and 
be transported within the double lipid layer6,7. Important 
cell functions are attributed to microdomains, such as cell 
signaling modulators, cell adhesion mediators and also 
antigenic function8.
Hakomori states that the GSLs, the gangliosid 
among them (GSLs with syalic acid residues), have their 
expression increased in tumors due to alterations in their 
glicosylation, observed along his 35 years of research, in 
vitro and in vivo changes in GSL glisosilation1,9.
It is well shown the aberrant glicosylation in 
melanomas through dissyaloganglioside (GD3) expres-
sion, gangliosid expressed in melanomas and not in the 
melanocyte. This ganglioside is related to the fast growth 
and especially to the undifferentiated and amelanocytic 
melanoma form, working as a tumor marker10,11. Colon, 
breast and lung malignant tumors also have GSLs as tu-
moral markers, and there is pre-clinical research about 
it12,13. For melanoma, for which research is more advanced, 
we already have vaccines produced with anti-GSL mono-
clonal antibody (MAb), approved for clinical use in Canada 
and Australia14.
However, as far as head and neck SCC (squamous 
cell carcinoma), especially in upper airways and digestive 
tracts, there are few papers showing GSL expression in the 
SCC differentiation or malignant transformation, despite 
the fact that one of the first antibodies developed against 
GSL be able to identify SCC LacCer1,15. Only Bolot et al. 
(1998, 1999) assessed GSL expression in head and neck 
carcinoma and normal tissue cells, notwithstanding these 
papers leave doubts in regards of histologic types and the 
anatomical sites of the tumors studied. 
Since the SCC GSL expression is not very much 
studied, we decided to carry out a prospective study aim-
ing at assessing SCC GSL expression in the upper airway 
and digestive tract. 
METHODS
We carried out a prospective study in 33 upper 
airway and digestive tract SCC samples and normal cells 
of patients operated at the Head and Neck Department 
- UNIFESP-EPM, of those 15 were larynx tumors, 9 were 
oropharynx, 3 hypopharynx and 6 oral cavity tumors. The 
patients were not separated as to age and gender. 
The collected material was processed in the gly-
cosphingolipids lab of the glycoconjugated Immunochem-
istry Sector – Biology Molecular Department – Federal 
University of São Paulo – Paulista School of Medicine. 
The material was homogenized and the GSL was 
extracted with the use of IPA/hexane/ H20 (55:20:25 v/v/v) 
twice and once with chloroform/methanol (2:1 v/v).
After extraction, the GSL was purified by reverse 
hydrolysis chromatography in C-18 column and methanol 
alkaline hydrolisis16,17. GSL quantification was carried out 
by HPTLC plaque densitometry, dyed with orcinol using 
Shimadzu CS 9000 densitometer at 525nm, having GM3 
(Sigma®) as standard reference in the concentration of 
0,1µg17,18. In order to better visualize the gangliosides, the 
plaques were dyed with resorcinol. The gangliosides were 
seen as purple spots19.
We analyzed the reactivity of GSL expressed for 
MAb DH2 (anti-GM3) by immune coloring of the HPTLC 
plaques and indirect immune fluorescence. 
With the GSL identified and quantified, we carried 
out the statistical study through the t-independent test, and 
(ANOVA) variance analysis with a 5% significance level. 
In order to identify sugar residues present in the 
normal mucosa and SCC CMH, the material was individual-
ized by preparative HPTLC and the CMH corresponding 
fraction was derived (metanolysis, re-N-acetilation and 
trimetylsylation) and analyzed in gaseous CP-3800 chro-
matographs coupled to Quadrupole MS 1200L Varian® 
(GC/MS) mass spectrometer.
The Ethics and Research Committee of the Federal 
University of São Paulo approved the study. 
RESULTS
Analyzing the data obtained we see that there was 
no difference in the GSL types expressed in SCC when we 
compare it to the normal mucosa, the main GSL expressed 
were GM3, globoside, CTH, CDH and CMH. However, we 
saw an increase in GSL expression in SCC, and thus it is 
possible to have an idea about this difference analyzing 
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the intensity of SCC GSL band coloring in relation to the 
normal mucosa (Figure 1).
We saw a significant increase in SCC GSL when 
compared to the normal mucosa. For this comparison we 
used the t-independent test, where p>0.001 (Table 1).
In order to determine which GSL are found signifi-
cantly increased in SCC, we used the ANOVA test, and 
its results proved to be significant for all effects. Through 
multiple comparisons we identified a greater expression 
of all GSL in SCC when compared to the normal mucosa, 
except for CMH (Graph 1).
Other gangliosides such as GM1 and GM2 were also 
expressed in some SCC samples, in smaller amounts.
The SCC and upper airway and digestive tract cells 
reactiveness to MAb DH2 (anti-GM3) is shown by imprint 
indirect immune fluorescence and by immune coloring of 
HPTLC plaques. We noticed the important difference in 
SCC expressed GM3 reactiveness when compared to that 
of the upper airway and digestive tract normal mucosa 
in both indirect immune fluorescence (Figures 2) and im-
mune coloring. There was no normal mucosa or SCC cells 
reactivity to  MAb MEST-1 (anti β-galactofuronose), used 
as inespecific antibody.
Sugar residues which are part of the CMH were 
analyzed by GC/MS, comparing the retention time of 
glucose and galactose patterns with the retention times 
obtained from CMH and SCC and that of the normal mu-
cosa. Through GC/MS we detected the presence of two 
peaks for each type of sugar, corresponding to the α and 
β isomers of each molecule, with retention times of 31.325 
and 31.977 for galactose (Gal), and 32.527 and 32.894 for 
glucose (Glc). We noticed both SCC glucosylceramide 
(GlcCer) and galactosylceride (GalCer) expressed, whilst 
the upper airway and digestive tract mucosa express 
glucosylceramide only. SCC GalCer represents 35% of the 
CMH fractions (Figure 3).
DISCUSSION
Alterations in both GSL structure and expression in 
cell neoplastic growth, differentiation and transformation 
is a well documented fact in the literature, being the goal 
of research for decades now9,20. However, as far as head 
and neck, and mainly upper airway and digestive tract 
SCC are concerned, there are just a few papers showing 
GSL expression in the SCC differentiation or malignant 
transformation process. 
The only two articles, of the same group, that 
assessed GSL expression in carcinoma cells compared 
to head and neck normal tissue, leave doubts as to the 
histological type and the anatomic sites of the tumors 
studied; besides, the small number of tumors studied by 
this group, six cases only, do not correctly represent SCC 
GSL expression21,22. Another description of SCC GSL ex-
pression profile was carried out when they studied GSL 
Figure 1. Orcinol/H2SO4 dyed HPTLC slide. (Left) and (right) resorcin 
dyed HPTLC - Pattern – erythrocyte GSL pattern. GM3 – GM3 Pat-
tern (Sigma®). SCC – SCC GSL. Normal mucosa normal – normal 
mucosa GSL.
Figure 2. Indirect immune fluorescence microphotography where 
we see the difference in SCC cell reactivity in comparison to normal 
mucosal cells with MoAb DH2 (AntiGM3). - A. DH2 immune dyed 
SCC cells (green). B. DH2 marked normal mucosa cells (green). C. 
DAPI dyed SCC cell nuclei (blue). D. DAPI dyed normal mucosa cell 
nucleus (blue).
Graph 1. Average of upper airway and digestive tract and SCC GSL 
quantity.
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Figure 3. CMH molecules mass spectrometry. The upper lines (A and 
B) show sugar residues identification in upper airway and digestive tract 
mucosa CMH fraction. Lines C and D correspond to the identification of 
sugar residues in SCC CMH fraction. Gal - galactose Glc - glucose.
Figure 4. Proposed diagram for the GSL synthesis pathway to explain 
the increase in these molecules expression in upper airway and di-
gestive tract and SCC. The greater lactosylceramide sinthasis activity 
would increase GM3, CTH and CDH expression and, consequently 
would reduce Glc supply for GlcCer synthesis, thus the SCC cells need 
to use Gal in order to produce GalCer and keep the cell membrane 
structure.
Figure 5. GSL quantity average in upper airway and digestive tract 
mucosa and SCC.
Figure 6. GSL quantity average in upper airway and digestive tract 
mucosa and SCC.
Figure 7. GSL quantity average in upper airway and digestive tract 
mucosa and SCC.
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expression during the differentiation process in SCC cells 
in the retromolar region20.
Our study showed a significant increase in SCC total 
GSL in the upper airway and digestive tract in relation to 
the normal mucosa, especially due an increase in GM3, 
globoside, CTH and CHD expressions. CMH is the only ex-
ception, because we detected similar quantities of it in both 
SCC and normal mucosa. Analyzing the aforementioned 
results and the ganglioside synthesis metabolic pathway, 
we may suppose that UDP-Gal: Glucosilceramidaβ1-
4galactosiltrasnferase (lactosylceramide sinthasis) activity, 
responsible for the addition of a galactose residue to Glc-
Cer, turning it into CDH, is increased due to the neoplastic 
transformation process. Contributing to this hypothesis 
is the fact of it having been found in the GalCer tumoral 
CMH fraction, suggesting that the GalCer would be syn-
thesized for GlcCer replacement, thus maintaining the cell 
membrane structure (Figure 4).
The increase in total GSL and the presence of CMH 
as GalCer was also seen by Bolot et al. (1998)22.
Confronting GSL expression seen in our work with 
literature data, the only difference found was the presence 
of GD3, seen by Tatsumura et al. (1988) and Bolot et al. 
(1998)20,22. And, as we analyze GSL expression in head 
and neck SCC fragment collection obtained from six pa-
tients, Bolot et al. (1999) found NAc-GM1 only in SCC, in 
minimal amounts21.
We attribute this ganglioside expression difference 
we saw in comparison to those described by Bolot et 
al. (1998 and 1999) and Tatsumura et al. (1988), to two 
aspects20-22:
1. For believing it to be more representative, we 
decided to identify the GSL in each harvested tissue frag-
ment and analyzed them individually, as Bolot et al. (1998 
and 1999) did, or according to Tatsumura et al. (1988) who 
employed SCC cell strains20-22.
2. There may really be differences in GSL expres-
sion, once the literature shows, quite well, the large dif-
ferences existing as to SCC genotype and phenotype, fact 
that has made it impossible to, so far, establish reliable 
and clinically useful conclusions23-25.
Bolot et al. (1998 and 1999) paper calls our attention 
to the quantity of GD3 similar to GM3, and this reinforces 
the hypothesis of a distinct pattern in GSL expression in 
the tumors studied by these authors, in relation to the 
samples analyzed in our study21,22.
Tatsumura et al. (1988) observed in SCC cell line-
age (SqCC/Y1) cultivated in a complete culture medium, 
a reduced GD3 expression. Only by cultivating SqCC/Y1 
cell lines in a culture medium without serum was possible 
to detect a significant increase in GD3 expression. 
It is curious to see GM3 increase in tumoral tissue, 
because its increase is related to the inhibition of the cell 
growth process. GM 3 inhibits epithelial growth factor re-
ceptors self phosphorilation26,27, and may induce apoptosis 
via Bcl-29. Another hypothesis, contrary to the previous 
explanation, is the possibility of GM3 act as a second 
messenger in the growth process regulation; however, we 
still need more detailed studies to prove the role of GM3 
in cell growth27.
The main possibility of using GSL to aid in the 
diagnosis and treatment of malignant neoplasia is based 
on structure alteration and/or GSL conformation, more 
precisely that of the carbohydrates presented in these 
molecules, thus allowing MAb production, that specifically 
recognizes tumor-related GSL. 
Because we had GM3 expression in both the mu-
cosa and in the SCC in this study, it would be expected a 
MAb DH2 reactivity proportional to the concentration of 
these GSLs in both tissues, however this was not observed 
(Figures 2). We believe that the difference in GM3 reactivity 
is justified by its conformational placement in the micro-
domains when expressed in greater quantity. We know, 
for instance, that the MAb M2590 (anti-GM3) only detects 
GM3 in the cells where there is relevant GSL expression, 
and there is the trend of this glycoconjugated in group-
ing itself in a way that is different in microdomains when 
there is any increase in its expression, thus, increasing 
MAb M2590 reactiveness. These results suggest the need 
of a critical concentration in order to achieve an optimum 
interaction with MAb DH2.28
As mentioned before, there is an increase in GM3 
expression in cell growth, and experimentally we have 
observed a DH2 (anti-GM3) inhibitory effect in melanoma 
cell growth in vivo and in vitro29. On the other hand, we 
saw that as we add GM3 to our culture medium, we have 
a cell growth inhibition. These results have contributed to 
the development of clinical and experimental research try-
ing to employ GSLs and mAbs (anti-GSL) in the diagnosis 
and treatment of malignant neoplasias1. As a result, we 
introduced mAbs specially guided against GSL and associ-
ated to different tumors. These tumor cells associated GSL 
guided mAbs have been used in cytological and pathology 
exams trying to differentiate benign lesions from malignant 
tumors17. Despite promising results, so far, the use of GSLs 
in cancer diagnosis and treatment is still restrict to some 
types of tumors, such as melanomas9,30,31.
The use of GSL as anticancer vaccines antigen2 is 
a possibility that has aroused the interest of the scientific 
community in current days. In a phase III study, in which 
we employed lung cancer associated antigens, we obtained 
a survival of 70% compared to 49% for stages I and II 
in 5 years32. The largest number of anticancer vaccines 
were developed and tested against melanoma cells, using 
mAbs anti-GM3, GM2 and GD3. Other vaccines have been 
produced against tumors such as, for instance, breast and 
intestine, however, they remain as clinical assays. 
Only in Canada and Australia there are clinically 
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approved anticancer vaccines for melanoma, where me-
tastasis patients had a survival increase of 25% to 50% in 
five years. Despite these promising results, most of the 
anticancer vaccines developed so far remain as research 
projects, not being approved by the north-American (FDA) 
and European regulating agencies for clinical use14.
Therefore, the possibilities of using GSL and MAb 
that recognize these GSL to help in the diagnosis and 
treatment of SCC is promising, as is the case with the 
melanoma, however, we need further SCC GSL structural 
and immunochemical research, as well as for the many 
types of head and neck tumors. 
CONCLUSION
The results from this research work allow us to 
conclude that there is a significant GSL expression in-
crease in upper airway and digestive tract SCC expression 
when compared to the normal mucosa of this region. This 
increase in expression happens especially in GM3, globo-
side, CTH, CDH; and the main hypothesis for this greater 
expression in malignant transformation processes would 
be related to an increase in Lactosylceramide synthase 
quantity and activity.
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